Sonoma Pharmaceuticals, Inc. (SNOA) - Q1 2026 Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025 (Fiscal Q1 2026). Sonoma Pharmaceuticals is a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for wound care, dermatology, eye care, podiatry, animal health, and surface disinfection. The company operates in 55 countries and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 (Ended June 30, 2025) | Q1 2025 (Ended June 30, 2024) |
|---|---|---|
| Total Revenue | $4.015 million | $3.391 million |
| Gross Profit | $1.464 million (36% margin) | $1.306 million (39% margin) |
| Net Loss | $(1.241) million | $(1.143) million |
| Net Loss Per Share (Basic/Diluted) | $(0.76) | $(1.34) |
| Cash and Cash Equivalents | $3.605 million | $2.589 million |
| Working Capital | $8.259 million | $8.176 million |
| Short-Term Debt | $0.139 million | $0.220 million |
| Accumulated Deficit | $(199.047) million | $(195.492) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 18% year-over-year, driven by a 57% increase in U.S. revenue ($1.005M vs $0.642M) and a 39% increase in Asia revenue. Latin America revenue declined 36% due to timing of customer orders.
- Expense Management: Selling, General, and Administrative (SG&A) expenses decreased 2% to $1.965 million, improving as a percentage of revenue from 59% to 49%. Research and Development (R&D) expenses increased 26% to $0.594 million to support new product releases.
- Cash Flow: Net cash used in operating activities increased to $2.015 million from $0.912 million, primarily due to higher inventory build-up ($0.652M) and prepaid expenses ($0.819M), partially offset by an increase in accounts payable.
- Other Income: Other (expense) income turned negative to $(0.147) million from $0.176 million, largely due to foreign exchange fluctuations, though partially offset by $0.323 million in employee retention credits.
Outlook, Risks, and Contingencies
- Liquidity and Going Concern: Management states there is substantial doubt about the company's ability to continue as a going concern within one year due to a history of losses and reliance on future financing. The company has an accumulated deficit of nearly $199 million and cash burn of approximately $2 million per quarter from operations.
- Capital Needs: The company anticipates needing additional capital through equity offerings, debt, or collaborations. Failure to secure funding could force cost-cutting measures that delay commercialization.
- Tax Liability: The company faces a substantial Mexico tax liability, intercompany debt, and accrued interest due in 2027. Management believes current assets are sufficient to cover this without interrupting operations.
- Recent Legislation: The "One Big Beautiful Bill Act" (OBBBA) enacted on July 4, 2025, changes U.S. tax laws. Management anticipates an insignificant immediate impact but is evaluating long-term effects.
- Customer Concentration: Three customers accounted for 43% of revenue in Q1 2026 (10%, 14%, and 19%).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.6 million cash balance against the ~$2 million quarterly operating cash burn and the "substantial doubt" going concern warning.
- Inventory Build: Investigate the $0.652 million increase in inventory and the $0.304 million allowance for obsolete inventory to ensure demand supports current stock levels.
- Customer Concentration: Assess the risk associated with the top three customers representing 43% of total revenue.
- Mexico Tax Exposure: Review the specific details of the deferred tax liability and intercompany debt due in 2027 mentioned in the "Material Trends" section.
- Reverse Stock Split Impact: Note the 20-for-1 reverse stock split effective August 29, 2024, which has been retroactively applied to all share data in this filing.